Eli Lilly & Co. (NYSE:LLY) 's dominance in obesity therapeutics looks increasingly difficult to challenge, and Bank of America believes the market is still underestimating just how much growth lies ahead.On Monday, the bank’s analyst Jason Gerberry reiterated a Buy rating on the stock, trimming his price objective slightly from $1,286 to $1,268. The adjustment wasn't about waning confidence. The stock was trading around $1,055 Monday.Instead, Gerberry said there remains "room for stock upside" as Lilly cont ...

Eli Lilly & Co. (NYSE:LLY) 's dominance in obesity therapeutics looks increasingly difficult to challenge, and Bank of America believes the market is still underestimating just how much growth lies ahead.On Monday, the bank’s analyst Jason Gerberry reiterated a Buy rating on the stock, trimming his price objective slightly from $1,286 to $1,268. The adjustment wasn't about waning confidence. The stock was trading around $1,055 Monday.Instead, Gerberry said there remains "room for stock upside" as Lilly cont ...